Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ADP-A2M4 cells|
Autologous MAGE-A4 C1032 TCR-modified T cells are autologous patient-derived T-cells that are modified to express a T-cell receptor that recognizes human melanoma antigen 4 (MAGE-A4), which may result in growth inhibition of MAGE-A4-expressing tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ADP-A2M4 cells||MAGE-A4 SPEAR T cells|autologous TCR-transduced MAGE-A4 C1032 T cells||ADP-A2M4 cells are autologous T-cells that are modified to express a T-cell receptor that recognizes the human melanoma antigen 4 (MAGE-A4) peptide region from 230-239, which potentially inhibits growth of MAGE-A4-expressing tumor cells (PMID: 32002290).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04044768||Phase II||ADP-A2M4 cells||Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma||Recruiting|
|NCT04044859||Phase I||ADP-A2M4 cells||Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors||Recruiting|
|NCT03132922||Phase I||ADP-A2M4 cells||MAGE-A4c1032T for Multi-Tumor||Recruiting|